Search clinical trials for: CD30 positive lymphoma

Total 21151 results

Fundació Institut de Recerca de l'Hospital de la...
Instituto de Salud Carlos III; Josep Carreras Leukaemia Research Institute

Recruiting

CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma.

Hodgkin Lymphoma, Adult | T Cell Lymphoma

Spain
Takeda

Completed

Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)

Hodgkin Disease | Lymphoma, Large-Cell, Anaplastic

China
Affimed GmbH

Completed

Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides (REDIRECT)

Peripheral T Cell Lymphoma | Transformed Mycosis Fungoides

Spain, United States, Korea, Republic of, Italy, France, Australia, Germany, Poland, Turkey, Russian Federation
Takeda

Completed

B-CD30 + Hodgkin Lymphoma International Multi-center Retrospective Study of Treatment Practices and Outcomes (B-HOLISTIC)

Classical Hodgkin Lymphoma | Relapsed or Refractory Classical Hodgkin Lymphoma

Korea, Republic of
Seagen Inc.
Millennium Pharmaceuticals, Inc.

Completed

A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study

Lymphoma, Non-Hodgkin | Lymphoma, Large-Cell, Anaplastic | Disease, Hodgkin

United States, France
New York Medical College
St. Baldrick's Foundation

Active, not recruiting

Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients

Hodgkin Lymphoma

United States
Shanghai Zhongshan Hospital
Takeda; BeiGene

Not yet recruiting

Efficacy and Safety of BV With Tislelizumab for the Treatment of CD30+ Relapsed/Refractory NK/T-cell Lymphoma

NK/T Cell Lymphoma Nos
Seagen Inc.
Bristol-Myers Squibb

Completed

A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma

Hodgkin Lymphoma

United States
M.D. Anderson Cancer Center

Active, not recruiting

Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Mycosis Fungoides | Refractory Mycosis Fungoides | Recurrent Classic Hodgkin Lymphoma | Refractory Classic Hodgkin Lymphoma | Refractory Anaplastic Large Cell Lymphoma | Recurrent Anaplastic Large Cell Lymphoma and other conditions

United States
UNC Lineberger Comprehensive Cancer Center

No longer available

Compassionate Use Re-Infusion of ATLCAR.CD30

Hodgkin Lymphoma, Adult

United States
Seagen Inc.
Millennium Pharmaceuticals, Inc.

Completed

ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas (ECHELON-2)

Non-Hodgkin Lymphoma | T-Cell Lymphoma | Anaplastic Large-Cell Lymphoma

United States, Korea, Republic of, Spain, United Kingdom, Taiwan, Czechia, Hungary, France, Israel, Germany, Italy, Denmark, Australia, Poland, Romania, Canada
Stichting Hemato-Oncologie voor Volwassenen Nederland

Recruiting

Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse (HOVON 136 NHL)

DLBCL

Netherlands
Seagen Inc.
Millennium Pharmaceuticals, Inc.

Completed

A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms

Lymphoma, Large-Cell, Anaplastic | Lymphoma, NK-cell | Lymphoma, T-cell

United States, United Kingdom
M.D. Anderson Cancer Center
Takeda

Withdrawn

Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas

Anaplastic Large Cell Lymphoma | Classical Hodgkin Lymphoma | Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic | CD30+ Peripheral T-cell Lymphoma
Seagen Inc.
Millennium Pharmaceuticals, Inc.

Completed

A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma

Disease, Hodgkin

United States, Canada
Takeda

Active, not recruiting

A Spanish Medical Record Review of Adults With Relapsed or Refractory CD30+ Malignancies When Re-treated With Brentuximab-vedotin (BELIEVE)

Hodgkin Disease | Lymphoma, T-Cell, Cutaneous

Spain
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma

United States
Deepa Jagadeesh

Recruiting

A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)

Angioimmunoblastic T-cell Lymphoma | T-cell Lymphoma | Adult T-cell Leukemia/Lymphoma | Enteropathy Associated T-cell Lymphoma | Hepato-splenic T-cell Lymphoma | NK T-cell Lymphoma

United States
Seagen Inc.
Millennium Pharmaceuticals, Inc.

Completed

A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)

Disease, Hodgkin

United States, United Kingdom, France, Romania, Poland, Italy, Bulgaria, Hungary, Russian Federation, Czechia, Spain, Germany, Serbia
Seagen Inc.
Millennium Pharmaceuticals, Inc.

Completed

A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma

Disease, Hodgkin

United States, France, Canada, Belgium, Italy
Millennium Pharmaceuticals, Inc.
Seagen Inc.

Completed

A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study) (ALCANZA)

Mycosis Fungoides | Cutaneous T-Cell Lymphoma | Primary Cutaneous Anaplastic Large Cell Lymphoma

United States, France, Italy, United Kingdom, Spain, Switzerland, Brazil, Austria, Belgium, Germany, Poland, Australia
Affimed GmbH
Artiva Biotherapeutics, Inc.

Recruiting

Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL (LuminICE-203)

Peripheral T Cell Lymphoma | Relapsed or Refractory Hodgkin Lymphoma

United States
Seagen Inc.

Completed

Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma

Hodgkin Disease

United States
The Lymphoma Academic Research Organisation

Completed

A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage III-IV HIV-associated Hodgkin Lymphoma (AMC-085)

HIV Infection | Stage III Adult Hodgkin Lymphoma | Stage IV Adult Hodgkin Lymphoma | HIV-associated Hodgkin Lymphoma

France
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma

Classic Hodgkin Lymphoma | Lymphocyte-Rich Classic Hodgkin Lymphoma | Ann Arbor Stage IB Hodgkin Lymphoma | Ann Arbor Stage II Hodgkin Lymphoma | Ann Arbor Stage IIA Hodgkin Lymphoma | Ann Arbor Stage IIB Hodgkin Lymphoma | Ann Arbor Stage I Hodgkin Lymphoma | Ann Arbor Stage I Mixed Cellularity... and other conditions

United States
University of Washington
National Cancer Institute (NCI); Seagen Inc.

Active, not recruiting

Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (BV-ICE)

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma

United States
National Cancer Institute (NCI)

Suspended

Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Recurrent Classic Hodgkin Lymphoma | Refractory Classic Hodgkin Lymphoma

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients With Stage I-II Hodgkin Lymphoma

Classic Hodgkin Lymphoma | Ann Arbor Stage IB Hodgkin Lymphoma | Ann Arbor Stage II Hodgkin Lymphoma | Ann Arbor Stage IIA Hodgkin Lymphoma | Ann Arbor Stage IIB Hodgkin Lymphoma | Ann Arbor Stage I Hodgkin Lymphoma | Ann Arbor Stage IA Hodgkin Lymphoma

United States
Seagen Inc.
Millennium Pharmaceuticals, Inc.

Completed

A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma

Lymphoma, Non-Hodgkin | Lymphoma, Large-Cell, Anaplastic

United States, France, Canada, Belgium, United Kingdom
Seagen Inc.
Millennium Pharmaceuticals, Inc.

Completed

Cardiac Safety Study of Brentuximab Vedotin (SGN-35)

Lymphoma, Non-Hodgkin | Lymphoma, Large-Cell, Anaplastic | Disease, Hodgkin

United States, Germany
National Cancer Institute (NCI)
The Lymphoma Academic Research Organisation

Active, not recruiting

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With Stage II-IV HIV-Associated Hodgkin Lymphoma

HIV Infection | Ann Arbor Stage III Hodgkin Lymphoma | Ann Arbor Stage IIIA Hodgkin Lymphoma | Ann Arbor Stage IIIB Hodgkin Lymphoma | Ann Arbor Stage IV Hodgkin Lymphoma | Ann Arbor Stage IVA Hodgkin Lymphoma | Ann Arbor Stage IVB Hodgkin Lymphoma | Classic Hodgkin Lymphoma | Ann Arbor Stage II Hodgkin... and other conditions

United States, France
Motif Bio

Completed

Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-1 (REVIVE-1)

Skin Structures and Soft Tissue Infections

United States, Bulgaria, Chile, Colombia, Germany, Latvia, Peru, Poland, Puerto Rico, Ukraine
Seagen Inc.

Terminated

Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)

Lymphoma, Large B-cell, Diffuse | Lymphoma, B-cell

United States, Spain, Italy, Czechia, Poland
M.D. Anderson Cancer Center
Seagen Inc.

Terminated

Phase I/II - Brentuximab/5-Azacytidine in Acute Myeloid Leukemia (AML)

Leukemia

United States
Seagen Inc.
Millennium Pharmaceuticals, Inc.

Completed

Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)

Neoplasms | Lymphoma, Non-Hodgkin | Lymphoma, Large-Cell, Anaplastic | Disease, Hodgkin | Carcinomas

United States
Lawson Health Research Institute
Seagen Inc.

Recruiting

Open Label Extension Study of Brentuximab Vedotin in Early dcSSc

Diffuse Cutaneous Systemic Sclerosis

Canada
Takeda
Takeda Development Center Americas, Inc.

Active, not recruiting

Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

Lymphoma

Belgium, Spain, Czechia, Hungary, Croatia, Portugal, Turkey, Poland, United Kingdom, Romania
Lawson Health Research Institute
Seagen Inc.

Completed

Brentuximab Vedotin in Early Diffuse Cutaneous Systemic Sclerosis

Diffuse Cutaneous Systemic Sclerosis

Canada
Seagen Inc.
Millennium Pharmaceuticals, Inc.

No longer available

A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001

Lymphoma, Non-Hodgkin | Lymphoma, T-Cell, Cutaneous | Lymphoma, Large-Cell, Anaplastic | Disease, Hodgkin

United States, United Kingdom, Belgium, Serbia, Australia, Bulgaria, France, Germany, Hungary, Italy, Poland, Romania, Russian Federation, Spain, Switzerland
Millennium Pharmaceuticals, Inc.

Completed

A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma

Hodgkin Lymphoma | Anaplastic Large-cell Lymphoma

Spain, Belgium, Lithuania
Northwestern University
Seagen Inc.; Robert H. Lurie Cancer Center

Unknown

Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma

Stage III Adult Hodgkin Lymphoma | Stage IV Adult Hodgkin Lymphoma | Stage II Adult Hodgkin Lymphoma | Adult Lymphocyte Depletion Hodgkin Lymphoma | Adult Lymphocyte Predominant Hodgkin Lymphoma | Adult Mixed Cellularity Hodgkin Lymphoma | Adult Nodular Sclerosis Hodgkin Lymphoma

United States
Seagen Inc.

Completed

A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma

Lymphoma, B-Cell | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin | Lymphoma, T-Cell

United States, Canada
M.D. Anderson Cancer Center

Recruiting

PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy (PACIFIC)

Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Lymphoma

United States
National Cancer Institute (NCI)

Completed

Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma

Anaplastic Large Cell Lymphoma, ALK-Positive | Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma | Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma | Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma

United States
National Cancer Institute (NCI)

Withdrawn

A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma

Recurrent Classic Hodgkin Lymphoma | Refractory Classic Hodgkin Lymphoma
National Cancer Institute (NCI)

Active, not recruiting

Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma

Ann Arbor Stage IIIB Hodgkin Lymphoma | Ann Arbor Stage IVA Hodgkin Lymphoma | Ann Arbor Stage IVB Hodgkin Lymphoma | Classic Hodgkin Lymphoma | Ann Arbor Stage IIB Hodgkin Lymphoma | Childhood Hodgkin Lymphoma

United States, Canada, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

Ann Arbor Stage III Hodgkin Lymphoma | Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma | Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma | Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma | Ann Arbor Stage IV Hodgkin Lymphoma | Ann Arbor Stage IV... and other conditions

United States, Canada, Puerto Rico
Millennium Pharmaceuticals, Inc.

Completed

A Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Hodgkin Lymphoma

Hodgkin Lymphoma

Poland, Spain, Malaysia, Turkey, Germany, Czechia, Thailand
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC

Terminated

Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma

Lymphoma

United States
National Cancer Institute (NCI)

Recruiting

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

United States, Puerto Rico, Canada

Search clinical trials for: CD30 positive lymphoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Israel

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations